These results are robust for a rare, locally aggressive neoplasm, and represent the first large randomized evidence that selective CSF1R inhibition may meaningfully decrease disease burden and improve function in TGCT (Gelderblom et al., 2024[40]). The gene discussed is CSF1R; the disease is neoplasm.